EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcomes associated with azithromycin use among patients hospitalized with non-severe community-acquired pneumonia

Ashwin Gupta, Emily Walzl, David Ratz, Jennifer Horowitz, Elizabeth McLaughlin, Tejal Gandhi, Lindsay Petty, Anurag Malani, David Paje, Preeti Misra, Scott Kaatz, Steven Bernstein und 3 weitere

Antimicrobial Stewardship & Healthcare Epidemiology · 2025-07 · 5 (S2) · s21-s21

DOI: 10.1017/ash.2025.218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Stewardship & Healthcare Epidemiology, online erschienen am 24.09.2025. Verfasst von Ashwin Gupta und 14 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Community-acquired pneumonia (CAP) is the leading infectious cause for hospitalization. Guidelines recommend use of a macrolide antibiotic with a beta-lactam for coverage of atypical organisms; however, data supporting macrolide coverage disproportionately include patients with severe CAP. Debate remains regarding the benefit of macrolide coverage among patients hospitalized with non-severe CAP.

Methods

We emulated a target trial to evaluate outcomes associated with azithromycin use among patients hospitalized with non-severe CAP between 7/2017 and 8/2024 across 69 hospitals in Michigan. Included patients had an ICD-10 discharge diagnosis code of pneumonia, >2 signs or symptoms of CAP, and radiographic findings. Patients with severe CAP, risk factors for multi-drug-resistant organisms, those not started on standard CAP therapy with a narrow-spectrum beta-lactam with or without azithromycin, or those initially receiving doxycycline were excluded. Time zero was the time of first antibiotic administration on encounter day 1 or 2. Groups receiving and not-receiving azithromycin were balanced using inverse probability of treatment weighting (IPTW) assessed using standardized mean differences (SMD). The primary outcome was time to clinical stability. Secondary outcomes included intensive care unit (ICU) transfer, 30-day rehospitalization, 30-day mortality, and protocol deviation (i.e., azithromycin initiation after time zero [no-azithromycin group], patients receiving

Zitieren

APA

Gupta, A., Walzl, E., Ratz, D., Horowitz, J., McLaughlin, E., Gandhi, T., Petty, L., Malani, A., Paje, D., Misra, P., Kaatz, S., Bernstein, S., Younas, M., Flanders, S., & Vaughn, V. (2025). Outcomes associated with azithromycin use among patients hospitalized with non-severe community-acquired pneumonia. Antimicrobial Stewardship & Healthcare Epidemiology, 5(S2), s21-s21. https://doi.org/10.1017/ash.2025.218

Vancouver

Gupta A, Walzl E, Ratz D, Horowitz J, McLaughlin E, Gandhi T, et al. Outcomes associated with azithromycin use among patients hospitalized with non-severe community-acquired pneumonia. Antimicrobial Stewardship & Healthcare Epidemiology. 2025;5(S2):s21-s21. doi:10.1017/ash.2025.218

BibTeX
@article{Gupta2025,
  author = {Gupta, Ashwin and Walzl, Emily and Ratz, David and Horowitz, Jennifer and McLaughlin, Elizabeth and Gandhi, Tejal and Petty, Lindsay and Malani, Anurag and Paje, David and Misra, Preeti and Kaatz, Scott and Bernstein, Steven and Younas, Mariam and Flanders, Scott and Vaughn, Valerie},
  title = {Outcomes associated with azithromycin use among patients hospitalized with non-severe community-acquired pneumonia},
  journal = {Antimicrobial Stewardship & Healthcare Epidemiology},
  year = {2025},
  volume = {5},
  number = {S2},
  pages = {s21--s21},
  doi = {10.1017/ash.2025.218}
}
Kostenlos starten →